TCIM
ABUS icon

TIAA CREF Investment Management’s Arbutus Biopharma ABUS Stock Holding History

TIAA CREF Investment Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$247K Sell
69,076
-27
-0% -$104 ﹤0.01% 2836
2018
Q4 		$265K Sell
69,103
-1,256
-2% -$6.19K ﹤0.01% 2803
2018
Q3 		$665K Sell
70,359
-8,087
-10% -$80.3K ﹤0.01% 2605
2018
Q2 		$573K Buy
+78,446
New +$467K ﹤0.01% 2728

Other funds holding ABUS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

TIAA CREF Investment Management's ABUS Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Arbutus Biopharma (ABUS) stake by 0.04% in Q1 2019, selling an estimated $104 and leaving 69,076 shares worth $247K. The position accounts for ﹤0.01% of the portfolio, ranked #2836.

TIAA CREF Investment Management first reported a position in ABUS in Q2 2018 and has held it in 4 quarters since. The position peaked at $665K in Q3 2018. 72 funds tracked by Wall St. Rank hold ABUS as of Q1 2019.

  • TIAA CREF Investment Management held 69,076 shares of Arbutus Biopharma worth $247K as of Q1 2019.
  • TIAA CREF Investment Management sold 27 Arbutus Biopharma shares in Q1 2019, an estimated $104.
  • Arbutus Biopharma made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2836 holding.
  • TIAA CREF Investment Management first reported a position in Arbutus Biopharma in Q2 2018 and has held it in 4 quarters since.
  • TIAA CREF Investment Management's Arbutus Biopharma position peaked at $665K in Q3 2018.
  • 72 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.